The stock options approved under the Inducement Grants have an exercise price per share equal to
The RSUs approved under the Inducement Grants vest over four years, 25% on the first anniversary of the date of grant and in three equal annual installments for the following three years on the anniversaries of the date of grant.
The Company granted the stock options and RSUs as inducement materials to an individual entering into employment with bluebird bio, Inc. in accordance with NASDAQ Listing Rule 5635(c)(4).
About bluebird bio, Inc.
bluebird bio is a human company powered by human stories. We’re putting our care and expertise to work across a spectrum of disorders including cerebral adrenoleukodystrophy, sickle cell disease, β-thalassemia and multiple myeloma using three gene therapy technologies: gene addition, cell therapy and (megaTAL-enabled) gene editing.
bluebird bio has additional nests in
Follow bluebird bio on social media: @bluebirdbio, LinkedIn, Instagram and YouTube.
bluebird bio is a trademark of bluebird bio, Inc.
Cautionary Note on Forward-Looking Statements
This press release includes forward-looking statements pertaining to the continued service of an employee and future vesting of inducement grants as well as to our business and operations, including the discovery, development, and commercialization of our product candidates. Such forward-looking statements can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect bluebird bio’s business, particularly those identified in the risk factors discussion in bluebird bio’s Annual Report on Form 10-K, as updated by our subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20210804006016/en/
Investors:
epingpank@bluebirdbio.com
or
Media:
jsnyder@bluebirdbio.com
Source: bluebird bio, Inc.